Table of Contents
ISRN Neurology
Volume 2013, Article ID 613456, 4 pages
Research Article

The Role of Phenytoin in the Treatment of Localization Related Epilepsy: An International Internet-Based Survey of Neurologists and Epileptologists

1Department of Neurology, University of Louisville, School of Medicine, Louisville, KY 40202, USA
2Division of Neurology, Department of Pediatrics, Tufts University, School of Medicine, 755 Washington Street, Boston, MA 02111, USA
3Department of Neurology, Children’s Hospital Boston and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA

Received 9 May 2013; Accepted 9 June 2013

Academic Editors: R. Saponara, T. Sugawara, and S. Tsirka

Copyright © 2013 Rohit R. Das et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Phenytoin (PHT) has been the most widely used medication to treat both partial and generalized seizures. However, over the past twenty years, a variety of new compounds have been released with comparable efficacy, fewer adverse effects, and more predictable pharmacokinetic properties. We surveyed neurologists and epileptologists to determine current practice patterns relating to the use of PHT using an online survey instrument. A total of 200 responses were obtained though response rates for each survey question varied. Of the respondents, 78.1% were epilepsy specialists; 60% were adult practitioners; and the remainder saw either, only children or both adults and children. For new onset partial seizures only 10 respondents said PHT would be their first or second choice, while 45% reported that they would not consider PHT. This study shows that in the era of newer medications, the role of PHT has been placed in the category of a reserve medication in intractable epilepsy.